BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26504026)

  • 21. Synthesis and activity of three new trinuclear platinums with cis-geometry for terminal metal centres.
    Hamad SA; Beale P; Yu JQ; Huq F
    J Biomed Sci; 2014 May; 21(1):41. PubMed ID: 24884683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate.
    Bodo J; Chovancova J; Hunakova L; Sedlak J
    Neoplasma; 2005; 52(6):510-6. PubMed ID: 16284698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on combination of platinum drugs cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models.
    Nessa MU; Beale P; Chan C; Yu JQ; Huq F
    Anticancer Res; 2012 Nov; 32(11):4843-50. PubMed ID: 23155250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced Accumulation of Cisplatin in Ovarian Cancer Cells from Combination with Wedelolactone and Resulting Inhibition of Multiple Epigenetic Drivers.
    Sarwar S; Alamro AA; Alghamdi AA; Naeem K; Ullah S; Arif M; Yu JQ; Huq F
    Drug Des Devel Ther; 2021; 15():2211-2227. PubMed ID: 34079223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on two new mixed ligand platinum compounds with a trans-geometry.
    Al-Shuneigat J; Yu JQ; Beale P; Fisher K; Huq F
    Med Chem; 2010 Sep; 6(5):321-8. PubMed ID: 20977416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, characterization, activities, cell uptake and DNA binding of trinuclear complex: [{trans-PtCl(NH(3))}(2)mu-{trans-Pt(NH(3))(2-hydroxypyridine)-(H(2)N(CH(2))(6)NH(2))(2)]Cl(4).
    Cheng H; Huq F; Beale P; Fisher K
    Eur J Med Chem; 2005 Aug; 40(8):772-81. PubMed ID: 16122580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, characterisation, activities, cell uptake and DNA binding of [[trans-PtCl(NH3)2] [mu-(H2N(CH2)6NH2)] [trans-PdCl(NH3)2](NO3)Cl.
    Huq F; Daghriri H; Yu JQ; Tayyem H; Beale P; Zhang M
    Eur J Med Chem; 2004 Nov; 39(11):947-58. PubMed ID: 15501544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines.
    Yunos NM; Beale P; Yu JQ; Huq F
    Anticancer Res; 2011 Dec; 31(12):4283-9. PubMed ID: 22199293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, characterisation, activities, cell uptake and DNA binding of a trinuclear complex: [[trans-PtCl(NH3)]2mu-[trans-Pd(NH3)(2-hydroxypyridine)-(H2)N(CH2)6NH2)2]Cl4.
    Cheng H; Huq F; Beale P; Fisher K
    Eur J Med Chem; 2006 Jul; 41(7):896-903. PubMed ID: 16730394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in the in vitro activity of platinum drugs when administered in two aliquots.
    Al-Eisawi Z; Beale P; Chan C; Yu JQ; Proschogo N; Molloy M; Huq F
    BMC Cancer; 2016 Aug; 16(1):688. PubMed ID: 27566066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models.
    Althurwi SI; Yu JQ; Beale P; Huq F
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
    Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-proliferative and pro-apoptotic effects from sequenced combinations of andrographolide and cisplatin on ovarian cancer cell lines.
    Yunos NM; Mutalip SS; Jauri MH; Yu JQ; Huq F
    Anticancer Res; 2013 Oct; 33(10):4365-71. PubMed ID: 24123004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antidepressants and platinum drugs.
    Engelmann BJ; Ryan JJ; Farrell NP
    Anticancer Res; 2014 Jan; 34(1):509-16. PubMed ID: 24403509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
    Tanaka T; Masuda H; Naito M; Tamai H
    Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.